Completed

A Genome-Wide Association Study in Wilms Tumor

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Other
Who is being recruted

Urogenital Diseases+14

+ Female Urogenital Diseases and Pregnancy Complications

+ Kidney Diseases

1 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Observational
Study Start: October 2009
See protocol details

Summary

Principal SponsorChildren's Oncology Group
Last updated: August 22, 2016
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 2009

Actual date on which the first participant was enrolled.

PRIMARY OBJECTIVES: I. To use a genome-wide association analysis to identify novel genetic variants that confer susceptibility to Wilms tumor. II. To improve our understanding of the genetic architecture and etiology of Wilms tumor. III. To facilitate the identification of genetic markers that are associated with an increased risk of developing of Wilms tumor and/or those at risk of aggressive disease, relapse, additional tumors and/or cancer in their offspring. OUTLINE: Samples are analyzed for single nucleotide polymorphism (SNP) profiling using real-time polymerase chain reaction (PCR) and multiplex ligation-dependent probe amplification (MLPA).

NCT01808079
Principal SponsorChildren's Oncology Group
Last updated: August 22, 2016
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1 patient to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsKidney DiseasesKidney NeoplasmsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplastic Syndromes, HereditaryUrogenital NeoplasmsUrologic DiseasesUrologic NeoplasmsNeoplasms, Complex and MixedGenetic Diseases, InbornFemale Urogenital DiseasesMale Urogenital DiseasesWilms Tumor

Criteria

1 inclusion criteria required to participate
3000 samples from the 1958 Birth Cohort (58C) and 3000 from the UK Blood Service control series (NBS)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Childrens Oncology Group

Philadelphia, United StatesOpen Childrens Oncology Group in Google Maps
CompletedOne Study Center